Please assess the completion status of the following clinical trial:

Trial Title: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinically definite multiple sclerosis diagnosed according to the McDonald criteria~* EDSS 4-7~* Pyramidal FS \>= 2~Exclusion Criteria:~* History of epileptic seizures~* MS relapse or change in disease modifying treatment (DMT) within 60 days~* cancer within five years~* uncontrolled hypertension~* clinically important cardiac, hepatic, renal or pulmonary disease~* pregnancy~* breast feeding~* concomitant treatment with cimetidine, carvedilol, propranolol and metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fampridine-SR (Type: EXPERIMENTAL): Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
- Placebo (Type: PLACEBO_COMPARATOR): In the intervention phase 50% will receive placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).